Clinical Trial

Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC

Name: Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC — clinical trial record (NCT07671092)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Early Phase 1

View on ClinicalTrials.gov →

Summary

This imaging study aims to assess the feasibility, biodistribution, and dosimetry of the imaging agent in subjects with metastatic UC, HR+ and HER2- breast cancer, TNBC, or NSCLC.

Protocol Amendment History 1 change

critical Primary endpoint(s) modified 2026-07-17

Trial Details

NCT Number	NCT07671092
Lead Sponsor	RayzeBio, Inc.
Conditions	Metastatic Urothelial Carcinoma, Breast Cancer, TNBC - Triple-Negative Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, NSCLC
Enrollment	40 participants
Start Date	2026-06
Primary Completion	2027-07 (estimated)
Study Completion	2027-10 (estimated)
Updated on ClinicalTrials.gov	2026-07-16